Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis.

ABSTRACT:

Background

Treatment failure of Mycobacterium avium complex (MAC) pulmonary disease occurs in about 30% of people with cystic fibrosis (CF) and may be a result of abnormal drug concentrations.

Methods

Prospective, cross-over, single-dose PK study of 20 pancreatic insufficient individuals with CF and 10 healthy controls (HC). CF subjects received simultaneous doses of oral azithromycin, ethambutol, and rifampin in the fasting state and with food and pancreatic enzymes, separated by two weeks. HC received fasting doses only. A non-compartmental model was used to estimate PK parameters of drugs and metabolites.

Results

Azithromycin maximum concentration (C_max ) was higher and rifampin C_max was lower in fasting CF subjects compared to HC, while other

SUBMITTER: Martiniano SL 

PROVIDER: S-EPMC8543792 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature